Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab's expanding contracted work improves medium- and long-term revenue visibility. Synspective added 20 dedicated Electron launches for 2028-31, bringing its total to 47; backlog reached $2.4 billion after more than $1 billion in Q2 and early-Q3 awards. Space Systems broadens the business beyond launches, while Neutron's medium-lift upside still depends on reaching operational orbit. x.com 

Rocket Lab keeps executing: the US Space Force awarded it a $397M contract to build multiple advanced Flatellite spacecraft for the SB-AMTI program, which detects and tracks airborne threats in real time, and to launch them on Neutron. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's record Q2 and Iridium deal show it becoming an end-to-end space and defense platform that can capture more value than a launch-only company. Q2 revenue hit a record $234M, up 62%, and backlog a record $2.36B after over $1B of new contracts. Iridium adds over $870M of annual L-band revenue tied to government and enterprise. Launch revenue fell 30% sequentially largely because more HASTE defense work is recognized over time; Mynaric integration weighs on near-term margins. x.com 

Rocket Lab's defense contracts and backlog position it to benefit from national-security spending. Its $2.36B backlog includes over 100 booked launches, with an $816M SDA satellite deal and a $266M Space Force HASTE deal for hypersonic testing. Despite the Neutron delay, its $36B valuation offers one of the space sector's best risk-reward setups: exposure to the same defense and space-infrastructure trend as SpaceX at a fraction of its valuation. Rocket Lab is headed above $100. x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.com